Versant Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Versant Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.6K	Hold	494	–	–	﹤0.01%	2212
2026 Q1	$6.86K	Sell	494 -116	-19%	-$1.85K	﹤0.01%	2290
2025 Q4	$9.91K	Sell	610 -123	-17%	-$2.01K	﹤0.01%	1997
2025 Q3	$11K	Sell	733 -168	-19%	-$2.05K	﹤0.01%	1897
2025 Q2	$10.5K	Buy	901 +569	+171%	+$5.17K	﹤0.01%	1870
2025 Q1	$2.47K	Hold	332	–	–	﹤0.01%	2241
2024 Q4	$1.99K	Buy	+332	New	+$1.83K	﹤0.01%	2061
2023 Q4	–	Sell	-71	Closed	-$387	–	1915
2023 Q3	$387	Sell	71 -236	-77%	-$1.56K	﹤0.01%	1742
2023 Q2	$2.06K	Buy	+307	New	+$2.28K	﹤0.01%	1366

Other funds holding ADPT

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

AWM

Affinity Wealth Management Wilmington, Delaware $776M AUM 43.59% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

EWM

Edge Wealth Management New York $594M AUM 24.92% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

ITFISA

Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna Warsaw $300M AUM 61.93% 1-Year Est. Return

Versant Capital Management's ADPT Position: Q2 2026 in Review

Versant Capital Management held its Adaptive Biotechnologies (ADPT) position steady in Q2 2026 at 494 shares worth $10.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2212.

Versant Capital Management first reported a position in ADPT in Q2 2023 and has held it in 9 quarters since. The position peaked at $11K in Q3 2025. 33 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

Versant Capital Management held 494 shares of Adaptive Biotechnologies worth $10.6K as of Q2 2026.
Versant Capital Management left its Adaptive Biotechnologies share count unchanged in Q2 2026.
Adaptive Biotechnologies made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2212 holding.
Versant Capital Management first reported a position in Adaptive Biotechnologies in Q2 2023 and has held it in 9 quarters since.
Versant Capital Management's Adaptive Biotechnologies position peaked at $11K in Q3 2025.
33 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.